SEC Form DEFM14A filed by Iris Acquisition Corp

4 - Iris Acquisition Corp (0001831874) (Issuer)

3 - Iris Acquisition Corp (0001831874) (Issuer)

3 - Iris Acquisition Corp (0001831874) (Issuer)

Highlights Company's Chronic Operational and Share Price Underperformance and the Need for New Skill Sets in the Boardroom to Help Chef Reach its Full Potential Nominates Four Highly Qualified, Independent Directors Who Would Bring Valuable Experience in Operations, Finance, Information Systems, Capital Allocation and Strategic Planning to the Board Legion Partners Asset Management, LLC, together with its affiliates (collectively, "we" or "Legion Partners"), is a significant shareholder of The Chefs' Warehouse, Inc. ("Chef", or the "Company") (NASDAQ:CHEF). Today, Legion Partners issued a public letter to the Company's shareholders announcing its nomination of four candidates to the Boa

NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (NASDAQ:IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15

Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma The transaction values the combined companies at a pro forma enterprise value of $334 million The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd. The transaction is expected to be completed in the first half of 2023 Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company develo